Transcriptomics

Dataset Information

0

Targeting YAP/TAZ-TEAD as a precision therapy approach in head and neck squamous cell carcinoma


ABSTRACT: Dysregulation of the Hippo pathway and the consequent activation of its downstream targets, the transcriptional co-activators YAP and TAZ (YAP/TAZ), drives oncogenic transcriptional programs upon binding TEAD transcription factors in multiple human malignancies. The recent development of small molecule TEAD inhibitors (smTEADi) provides an opportunity to therapeutically target Hippo pathway dysregulation in cancer. In this regard, HPV-negative head and neck squamous cell carcinoma (HNSCC) harbor multiple genetic alterations that promote YAP/TAZ hyperactivation, raising the possibility that HNSCC cells might be dependent on YAP/TAZ-TEAD driven oncogenic transcriptional programs. To test this hypothesis, we examined the antitumor activity of the novel smTEADi, SW-682 and genetically encoded TEAD inhibitor peptide (pTEADi) in Cal33 HPV-negative HNSCC cell line-derived xenograft model. To elucidate the transcriptomic changes upon YAP/TAZ-TEAD inhibition, RNA extracted from xenograft tumors treated with SW-682 or pTEADi, as well as control, was subjected to RNA sequencing.

ORGANISM(S): Homo sapiens

PROVIDER: GSE277859 | GEO | 2024/10/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-10-04 | GSE222960 | GEO
2023-10-04 | GSE222962 | GEO
2017-06-20 | E-MTAB-5395 | biostudies-arrayexpress
2014-04-02 | E-GEOD-56445 | biostudies-arrayexpress
2022-07-17 | GSE182900 | GEO
2023-03-19 | PXD033939 | Pride
2019-06-17 | E-MTAB-7614 | biostudies-arrayexpress
2023-04-26 | GSE229071 | GEO
2017-04-19 | PXD003872 | Pride
2017-05-02 | PXD003864 | Pride